Impact of Doravirine in Liver Steatosis and Fibrosis in PLWH. A pilot, proof of concept study (DORALI Study)

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504952-87-00

Acronym

DORALI

Enrollment

Registered

2024-03-11

Start date

2025-01-13

Completion date

Unknown

Last updated

2024-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human Immunodeficiency Virus

Brief summary

Liver steatosis measured and liver fibrosis measured by CAP (Controlled Attenuation-Parameter, expressed in db/m) and transient elastography respectively

Detailed description

Fat liver content by MRI, Lipoprotein particles at week 48

Interventions

DRUGBiktarvy 50 mg/200 mg/25 mg film-coated tablets

DRUGDescovy 200 mg/25 mg film-coated tablets

DRUGPifeltro 100 mg film-coated tablets

DRUGDelstrigo 100 mg/300 mg/245 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Liver steatosis measured and liver fibrosis measured by CAP (Controlled Attenuation-Parameter, expressed in db/m) and transient elastography respectively	—

Secondary

Measure	Time frame
Fat liver content by MRI, Lipoprotein particles at week 48	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026